Clinical Trials · NCT03560336
A Regulatory Post-marketing Surveillance (rPMS) Study to Evaluate the Safety and Effectiveness of Saxenda®(Liraglutide 3.0 mg) in Obese Patients and Overweight Patients With Obesity-related Comorbidities in Routine Clinical Practice in Korea.
- Phase
- N/A
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 758
- Start date
- Jul 2018
- Locations
- 28 sites, South Korea
- Primary endpoint
- Incidence of adverse events (AEs) by preferred term (PT)